Clinical trial
Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in…
NCT00000893 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00000893 |
|---|---|
| Title | Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children |
| Official title | A Phase I/II, Open-Label, AUC-Controlled Study to Determine the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in Children |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Nelfinavir mesylate, Efavirenz |
| Enrollment | 103 |
| Start date | Oct 1, 1997 |
| Completion | Dec 1, 2002 |
| First posted | Aug 31, 2001 |
| Last update posted | Oct 29, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: